Welcome

Our Mission

The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) is an international group of rheumatologists and immunologists with special interests in lupus who have been working together on lupus research since 1991. Our mission statement is:

Towards a better world for people with lupus through prevention and improved outcomes

Join us in our mission. We at SLICC, rely completely on the generosity and support of our donors and funders to continue our work.

SLICC developed the Damage Index – the only internationally accepted way of measuring the long-term effects of lupus and its treatment on the body. Without this index, it would be impossible to study those effects over time and compare them between different countries, geographies, and ethnic groups.

SLICC carried out the largest ever study of cancer in patients with lupus – this taught us that only some cancers are more likely to occur in patients with lupus and that the drugs commonly used to treat this disease do not significantly increase this risk of cancer.

But to continue our work, to answer the questions that patients with lupus are asking, we need to invest.

DONATE
History & Objectives

About SLICC

Since its inception over 25 years ago, SLICC has evolved into a dynamic and expanding research group helping to promote lupus research and collaboration between scientific investigators. Over its history, SLICC has contributed to the development of multiple standardized outcome measures to better characterize lupus activity and damage as well as its response to varying treatments.

ABOUT US
 
Current Activities

SLICC’s Research

SLICC is dedicated to generating new knowledge in the field of lupus, and translating these basic and clinical research discoveries into better health care practices and policies to help provide a healthier future for people diagnosed with lupus.

In 1998, the SLICC group established a longitudinal cohort of newly diagnosed patients with lupus (SLICC Inception Cohort) to better understand risk factors for atherosclerosis and metabolic syndrome, and characterize nervous system involvement.

Our current research activities are focused on atherosclerosis, nervous system involvement, lupus nephritis, and damage accrual, and their economic impact using the inception cohort. New initiatives include development of a pregnancy cohort and working group on microparticles as well as revision of the SLICC/American College of Rheumatology (ACR) Damage Index (SDI).

 
SLICC Group

Organizational Structure

SLICC consists of a Board of Directors and 3 standing committees.

View Governing Body
SLICC Group

Membership

SLICC is an international research organization with 54 members who, collectively, represent 43 academic medical centres across 16 countries and 5 continents.

VIEW MEMBERS
THE LATEST

NEWS & EVENTS

Oct 19, 2018

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn’s disease. IL-12 and IL-23 have been implicated in systemic lupus erythematosus. We aimed to assess the efficacy and safety of ustekinumab for the treatment of systemic lupus erythematosus in patients with moderate-to-severe disease activity despite conventional treatment.

Oct 19, 2018

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)

Systemic lupus erythematosus (SLE) is a complex multisystemic autoimmune disease resulting, oftentimes, in irreversible damage, diminished quality of life and reduced life expectancy.1–3 Genetic and environmental factors play important roles in its pathogenesis.4–8 Disease manifestations and severity vary according to the patients’ racial/ethnic background and socioeconomic status (SES).

Oct 19, 2018

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Systemic lupus erythematosus is a multisystem, chronic autoimmune disease characterised by the presence of antibodies directed at self-antigens, and broad immune dysregulation. It is believed that abnormalities of both the innate and adaptive arms of the immune system, interconnected by a positive feedback loop, contribute to disease pathogenesis.